


A STUDY OF B - AGONIST DRUGS IN  
COMMON USE ON PULMONARY FUNCTION  
TESTS IN ASTHMATIC EGYPTIAN  
CHILDREN USING VITALOGRAPH

11/11/14

Thesis submitted  
for the partial fulfilments of Master Degree  
in pediatrics

*[Handwritten signature]*

By  
Samia Youssef Abdel Sayed  
M.B., B.Ch.



SUPERVISED BY  
Ass. Prof. Dr. Karima Ahmed Abdel Khalek  
Ass. Prof. Of Pediatrics  
Faculty of Medicine  
Ain SHams University

618-9223  
S.Y

25405

FACULTY OF MEDICINE  
AIN SHAMS UNIVERSITY

1986

1-52

**ACKNOWLEDGEMENT**

Foremost, I wish to record my great indebtedness and gratitude to my supervisor, Professor Dr. **KARIMA ABD EL KHALEK**, Assistant Professor of Pediatrics, Faculty of Medicine, Ain Shams University, who suggested the subject of this work, for her valuable guidance, interest and constructive criticism given to me at every stage of this work. For all that, I shall forever be grateful to her.

To ~~e~~very one who participated in some way or another, to let this work come to such a final picture, I owe my thanks and my gratitude.



## CONTENTS

	<u>Page</u>
Introduction.....	1
Review of Literature.....	4
1. Beta agonist drugs.....	4
2. Side effects of beta agonist drugs.....	11
3. Side effects after abuse of B. agonist drugs..	26
4. Concomitant use of beta adrenergic agonist and theophylline .....	34
5. Comparison between B agonist drugs in common use.....	43
A. As regard the action.....	43
i. Comparison between salbutamol and iso- prenaline.....	43
ii. Comparison between salbutamol and Ter- butaline.....	43
iii. Comparison between salbutamol and met- aproterenol.....	45
B. As regard route of administration.....	46
i. Comparison between oral and inhalation route.....	49
ii. Comparison between parenteral and inha- lation route.....	54
iii. Comparison between two types of inhala- tion .....	54
C. As regard side effects.....	59

	<u>Page</u>
Subjects and method.....	63
Results.....	68
Discussion.....	85
Conclusion and Recommendations.....	95
Summary.....	96
References.....	99
Arabic Summary	

o o o o o

## INTRODUCTION

Asthma is leading cause of chronic illness in childhood. It is responsible for a significant proportion of school days lost because of chronic illness.

Also asthma can lead to severe psychological disturbances in the family.

During acute attacks of experimentally-induced asthma, the predominant site of induced constriction may be either in the central or peripheral airways. During remission between spontaneous asthmatic attacks, there is evidence that considerable obstruction may be present in peripheral airways. Although other studies showed that acute constriction of the central airways may be mediated by a vagal reflex mechanism, the pathophysiology of peripheral airways obstruction in asthma is less well understood and may be caused by mucous secretions, edema, inflammatory exudates, fibrosis and/or bronchospasm with varying degrees of reversibility in reversible obstruction airways

disease either the large or small airways may be the major site of obstruction, in contrast to chronic irreversible obstructive airway disease in which the small airways are nearly always principally involved. In further studies of maximal expiratory flow responses to helium-oxygen breathing in asthmatic subjects. It was found that the large airways were the major site of obstruction in those asthmatic subjects without a history of cigarette smoking, chronic bronchitis or repeated respiratory tract infection, whereas the small airways were principally narrowed in asthmatic subjects in whom these factors were present. These workers pointed out, however, that the predominance of obstruction in the large airways of some asthmatic subjects does not exclude the presence of peripheral airways obstruction and that obstruction in small airways is not necessarily irreversible. (Tashkin et al., 1980).

With proper treatment, however much relief can be provided. Long term maintenance therapy of asthma with B adrenoceptor stimulants is commonly practiced in Europe. These drugs can be administered in several forms.

The aim of this work is to study the effects and side effects of an adrenergic B stimulants.

Also comparison between drugs and routes of administration of B adrenoceptor stimulants will be discussed.

## REVIEW OF LITERATURE

### B agonist drugs:

It has been suggested that the B receptor is either actually located on the enzyme adenylyl cyclase or is closely associated if not an integral component of the adenylyl cyclase system itself i.e. according to one hypothesis the B receptor is an integral part of adenylyl cyclase system. However other investigators tend to favour the view that the B adrenergic receptor is a separate entity from adenylyl cyclase and that adenylyl cyclase is only one of the many systems that are affected by it.

Activation of both  $B_1$  and  $B_2$  receptors results in activation of adenylyl cyclase and increased conversion of ATP to cAMP. Activation of the cyclase enzyme is mediated by a stimulatory guanine nucleotide-dependant coupling protein similar to the inhibitory "N" protein identified with certain  $\alpha_2$  receptors. cAMP is the major "second messenger" of beta receptor activation (Hoffman, 1986).

Stimulation of B<sub>1</sub> receptors produces:

- a- increase rate of heart through action on S.A node (chronotropic action).
- b- increase force or increase contractility (inotropic action).
- c- increase conduction velocity and shortening of functional refractory period (arrhythmogenic action).

Stimulation of B<sub>2</sub> receptor produces:

- a. vasodilation chiefly in skeletal muscle, and coronary bed.
- b. bronchial relaxation.
- c. uterine relaxation.
- d. Intestinal relaxation (in the intestine both  $\alpha$  and B<sub>2</sub> receptors exist leading to intestinal relaxation).

Examples of B agonist drugs on common use:

(1) Isoproterenol (Isuprel):

Isoprenaline has comparatively short bronchodilator action because it is rapidly metabolized by the enzyme catechol-O-methyl transferase, moreover,

in addition to being a powerful stimulator of  $B_2$  adrenergic receptors leading to bronchodilatation it also stimulates  $B_1$ -receptors in the myocardium, leading to tachycardia and a rise in cardiac output (Aviado and Schmidt, 1957; Kelman et al., 1969). This side effect is due to a direct result of the cardiac effects. Hypoxaemia may become worse after isoprenaline even though airway obstruction is diminished, when large doses are given, particularly when the patient is hypoxaemic, serious cardiac complications such as ventricular fibrillation or ventricular asystole may occur. The recent rise in asthma mortality coincided with the widespread use of portable pressurised aerosols containing most frequently, isoprenaline and it is relatively inactive orally and is usually administered by inhalation as aerosol of (1:100 or 1:200 aqueous solution) or it is administered via subcutaneous injection route or sublingually (Jegge et al., 1971).

(2) Metaproterenol (Alupent):

Metaproterenol possesses slightly more  $\beta_2$  specificity than does isoproterenol, but again, still exerts some  $\beta_1$  activity. It is marketed for oral

use (0.5 mg/kg/6 hrs.), S.C. injection and aerosol administration (Lefcoe et al., 1982). Studies involving aerosol administration of metaproterenol to asthmatic children generally report greater improvement in pulmonary function and a longer duration of action than isoproterenol (Passamonte and Marting, 1984).

(3) Isoetharine (Bronkosol):

Isoetharine is not much more selective beta agonist than isoproterenol. It is less potent than isoproterenol, It has a shorter duration of action (Galant, 1983). Isoetharine is used in the aerosol form.

(4) Terbutaline (Bricanyl):

Fortunately, small chemical changes in the isoprenaline molecule have lead to a series of related compounds which have to a large extent overcome the disadvantages of isoprenaline. Substitution of other groups or rearrangements of the existing groups in the benzene ring have rendered the compounds more resistant to the action of catechol-O-methyl transferase, thus prolonging their action, changes

in the side chain have increased their specificity for the  $B_2$  or bronchial as opposed to the  $B_1$  or cardiac receptors. A dose of (0.075 mg/kg) is administered orally 3 times daily, subcutaneously (0.25 mg) or as an aerosol (1 mg/ml dilution) and all of them produce marked improvement in ventilatory function over a few hours span. (Legge et al., 1971).

(5) Salbutamol (Ventoline):

Salbutamol has  $\beta_2$  adrenergic selectivity similar to that of terbutaline. It can be administered orally (0.2 mg every 6-8 hours), subcutaneously (1.75 mg/kg) or as an aerosol (Palmer et al., 1970). The bronchodilator effect of salbutamol was greater when patients received nebulized salbutamol. Its side effects are similar to those of terbutaline. (Grimwood et al., 1981).

(6) Fenoterol (Berotec):

Modern selective  $B_2$  receptor stimulator Fenoterol play an important role in the treatment of bronchial asthma. They have a good and dependable clinical effect, and there are no serious side effects were reported. Subjective discomfort due to tremor

or slight tachycardia may occur but can be handled by dose reduction. This  $B_2$  receptor stimulator is known to have a long duration of action and in clinical trials there is often not a complete return to the initial expiratory flow values even 8 hr after inhalation of the active substance. It can be argued whether the long lasting improvement during daytime is an effect of the bronchialating substance alone or if diurnal variation in bronchial tonus has a strong positive influence on the expiratory flow, thus simulating a long duration of action of the inhaled active substance. (Graff and Lonnevig, 1979).

(7) Bitolterol mesylate:

Bitolterol mesylate is a "prodrug" that is hydrolyzed by an esterase which has its highest concentration in the lungs, to a catecholamine with marked selectivity for  $\beta_2$ -adrenergic receptors. It differs from epinephrine in having a large N-alkyl substituent that increases  $B_2$  selectivity. The vulnerable catechol hydroxyl groups are protected by di-p-toulate esters, which decrease susceptibility to inactivation by catechol-O-methyltransferase. These properties result in a high concentration

of the active drug in the lungs and in prolonged bronchodilator activity with negligible side effects. (Kemp et al., 1984).

(8) Procaterol: is a new potent, long-lasting non-catecholamine B<sub>2</sub> agonist which has been developed in Japan. The only significant side effect noted was tremor. (Barbera et al., 1984).